Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02316327
Recruitment Status : Completed
First Posted : December 12, 2014
Last Update Posted : October 5, 2016
Sponsor:
Information provided by (Responsible Party):
Dr. Noemi Reguart, MD, PhD, Fundacion Clinic per a la Recerca Biomédica

Brief Summary:

RATIONALE: Classically the evaluation of response in lung cancer has been based in comparing pre & post treatment tumour volume by means of studying changes in the diameter of the selected target lesions by RECIST. The introduction of new targeted drugs creates the need of a different response assessment. Functional imaging techniques are able to study in vivo physiological processes of angiogenesis. Therefore, dynamic techniques may be more appropriate for assessing response to antiangiogenic drugs, whose mechanism of action is focused on tumor's vasculature normalization. Preliminary studies have demonstrated significant and very early changes in indirect vasculature parameters such as flow, blood volume and tumor perfusion with vascular-targeting agents. These techniques may be useful for selecting patients who are going to benefit from antiangiogenic therapy by an early evaluation of response by means of functional imaging method.

PURPOSE: IMPACT is an open-label, single arm phase II/IV study to evaluate the predictive value and early radiologic response or perfusion computed tomography (CT) in patients diagnosed with unresectable advanced, metastatic or recurrent non-squamous NSCLC treated with bevacizumab in combination with chemotherapy.


Condition or disease Intervention/treatment Phase
Non-Small Cell Lung Cancer (NSCLC) Drug: gemcitabine, cisplatin and bevacizumab Phase 4

Detailed Description:

OBJECTIVES

Primary objective:

• To assess early tumour response (at day +7) in terms of blood flow as compared to Objective Response Rate (ORR) in terms of RECIST criteria (CR + PR) at day 42.

Secondary objectives:

  • To assess early tumour response (at day +7) in terms of blood volume, mean transit time, enhancement peak, time to the enhancement peak and capillary tumour permeability as compared to ORR (CR + PR) at day 42.
  • To assess tumour response (at day +42) in terms of blood flow, blood volume, mean transit time, enhancement peak, time to the enhancement peak and capillary tumour permeability as compared to ORR (CR + PR) at day 42.
  • To assess tumour response (at day +7 and +42) in terms of blood flow, blood volume, mean transit time, enhancement peak, time to the enhancement peak and capillary tumour permeability as compared to PFS and OS
  • Safety profile using NCI-CTC AE (version 4.0).
  • To assess the efficacy in the subgroup of adenocarcinoma pts.

Outline:

Patients receive bevacizumab 7.5mg/kg IV, cisplatin 80mg/m2 and gemcitabine 1250 mg/m2 on days 1 and 8 up to 6 cycles of 21 days. Patients without progression may continue maintenance treatment with single-agent bevacizumab 7.5 mg/Kg on day 1 every 21 days.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 19 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase IV/II Open-label Study to Evaluate Prompt Response to Treatment With Cisplatin, Gemcitabine and Bevacizumab in Patients With Non-small Lung Cancer.
Study Start Date : July 2013
Actual Primary Completion Date : September 2016
Actual Study Completion Date : October 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arm Intervention/treatment
Experimental: gemcitabine, cisplatin and bevacizumab

Bevacizumab will be given by I.V infusion at the dose of 7.5 mg/kg on days 1 every 21 days

Cisplatin 80 mg/m2 I.V on day 1

Gemcitabine 1250 mg/m2 I.V on day 1 & 8

Treatment cycles will be repeated every three weeks up to 6 cycles

Bevacizumab monotherapy as maintenance allowed in non-progressive tumors

Drug: gemcitabine, cisplatin and bevacizumab
Therapeutic
Other Name: Avastin




Primary Outcome Measures :
  1. To evaluate blood supply, blood volume, time to peak flow increase and permeability and relation with the objective response to treatment (RC+RP) [ Time Frame: The results on baseline and day 7 to treatment in terms of blood suply, blood volume, time of peak flow increase and permeability and relation with the objective (RC+RP) at day 42. ]

Secondary Outcome Measures :
  1. To evaluate the response to treatment in terms of blood supply, blood volume and time to peak flow increase and permeability. [ Time Frame: To evaluate at day +42 the response to treatment in terms of blood supply, blood volume and time to peak flow increase and permeability. ]
  2. To evaluate the blood supply, blood volume, time to peak flow increase, permeability related with PFS and OS. [ Time Frame: To evaluate the blood fluid, blood volume, time to peak flow increase, permeability at baseline visita related with PFS and OS. ]
  3. To evaluate the response to treatment at day +7 and +42 in terms of blood fluid, blood volume, time to peak flow increase, permeability at baseline visit related with PFS and OS. [ Time Frame: To evaluate the response to treatment at day +7 and +42 in terms the blood fluid, blood volume, time to peak flow increase, permeability at baseline visita related with PFS and OS. ]
  4. The safety of the treatment following NCI-CTC AE (version 4.0) [ Time Frame: The safety of the treatment following NCI-CTC AE (version 4.0) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Give the written informed consent to participate in the trial before carrying out any specific study procedure.
  2. Histological or cytological non microcytic lung cancer (NMLC) and non squamous advanced locally or metastatic (IIIB/IV) lung cancer confirmation
  3. Capability to take on the obligations with study protocol requirements.
  4. Patients 18 years old.
  5. ECOG functional status 0 or 1.
  6. At least a measurable lung lesion with conventional TAC (i.e. ≥ 1cm) in at least one dimension its RECIST criteria (v.1.1) which has not been irradiated.
  7. Appropriate bone marrow function.
  8. Appropriate hepatic function.

10. International normalized ratio (INR) ≤ 1.5 and activate partial thromboplastin time (aPTT) ≤ 1.5 x UNL 7 days previous to the first study drug administration, unless patients have been used prophylactic anticoagulant treatment 11. Patients with brain metastasis which had been treated and also asymptomatic , they are eligible to participate in the study.

12. Female patients cannot be pregnant nor lactating. 13. Male fertile patients have to use a high effective method of contraception.

Exclusion Criteria:

  1. Previous treatment with systemic chemotherapy for advance NMLC
  2. Non microcytic- microcytic mix histology or adeno-squamous mix carcinomas with a predominant squamous component
  3. Hemoptysis history ≥ grade 2 (defined as at least 2.5 ml of bright red blood) in a period of 3 months prior to receive the study drugs
  4. Surgery (including open biopsy) or significant traumatic injury in a period of 28 day prior to receive the study drugs.
  5. Minor surgery including a catheter insertion in a period of 24h prior to the first infusion of bevacizumab
  6. Proof that the tumor can compress or invade a main vessel in image tests
  7. Radiotherapy in any site for any reason in a period of 28 days prior to receive the study drugs. It is permitted palliative radiotherapy to bone lesions .
  8. Aspirin based medication (> 325 mg/day or clopidogrel > 75mg/day) present or recent (in a period of 10 days from the first bevacizumab infusion). Medication with oral anticoagulants agents or parenteral medication on full doses (e.g. in a therapeutic range) or the use of thrombolytic agents with present and recent therapeutic intentions (in a period of 10 days prior to the first bevacizumab infusion). The prophylactic medication with anticoagulants is permitted
  9. History or evidence of inheritance bleeding diathesis or coagulopathy with bleeding risk
  10. Active gastrointestinal bleeding
  11. Inadequate controlled hypertension .
  12. Cardiovascular disease .
  13. Wounds that do not heal, active peptide ulcer or non treated bone fractures.
  14. History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess in the 6 months prior to receive the study drugs
  15. Known hypersensitivity to bevacizumab, cisplatin or gemcitabine or any of its excipients
  16. Important known hypersensitivity to iodated contrast agents
  17. Another neoplastic disease other than NMLC in a period of 5 years prior to receive the study drugs with exemption of in situ cervix carcinoma, basal or squamous skin cancer, prostate cancer treated with curative intention and in situ breast ductal carcinoma treated with curative intention
  18. Proof of any other disease, neurologic or metabolic dysfunction, lab abnormality or physical test that can reasonably make suspect circumstances that would contraindicate the use of a certain investigational or the standard treatment used in this study or that puts the patient into a greater risk to suffer complications related to the treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02316327


Locations
Layout table for location information
Spain
Hospital Clinic
Barcelona, Spain, 08036
Sponsors and Collaborators
Fundacion Clinic per a la Recerca Biomédica
Investigators
Layout table for investigator information
Principal Investigator: Noemi Reguart, MD, PhD Hospital Clinic

Publications:

Layout table for additonal information
Responsible Party: Dr. Noemi Reguart, MD, PhD, Oncologist, Fundacion Clinic per a la Recerca Biomédica
ClinicalTrials.gov Identifier: NCT02316327     History of Changes
Other Study ID Numbers: IMPACT
2012-000459-15 ( EudraCT Number )
First Posted: December 12, 2014    Key Record Dates
Last Update Posted: October 5, 2016
Last Verified: October 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Gemcitabine
Cisplatin
Bevacizumab
Antineoplastic Agents
Antineoplastic Agents, Immunological
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors